Clinical Characteristics and Comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems
Hogarth et al.,
Clinical Characteristics and Comorbidities associated with SARS-CoV-2 breakthrough infection in the University..,
The American Journal of the Medical Sciences, doi:10.1016/j.amjms.2023.04.019
Retrospective 110,380 patients in the USA, showing higher risk of COVID-19 breakthrough cases with vitamin D deficiency.
Authors note that "lockdown measures pose an increased risk for individuals to develop vitamin D deficiency".
This paper was delayed by peer review >10 months.
This is the
175th COVID-19 sufficiency study for vitamin D, which collectively show higher levels reduce risk with
p<0.0000000001 (1 in 18 vigintillion).
risk of case, 46.5% lower, OR 0.53, p < 0.001, high D levels (≥20ng/mL) 96,894, low D levels (<20ng/mL) 13,486, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), breakthrough case, multivariable, RR approximated with OR.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Hogarth et al., 3 May 2023, retrospective, USA, peer-reviewed, median age 56.0, 9 authors, study period 1 January, 2021 - 8 November, 2021.
Contact:
rongkeko@health.ucsd.edu (corresponding author).
Abstract: Journal Pre-proof
Clinical Characteristics and Comorbidities associated with
SARS-CoV-2 breakthrough infection in the University of California
Healthcare Systems
Michael Hogarth M.D. , Daniel John , Yuxiang Li ,
Jessica Wang-Rodriguez M.D. , Jaideep Chakladar B.S., M.S. ,
Wei Tse Li B.S., M.S. , Sanjay R. Mehta M.D. , Sharad Jain M.D. ,
Weg M. Ongkeko M.D., Ph.D.
PII:
DOI:
Reference:
S0002-9629(23)01166-7
https://doi.org/10.1016/j.amjms.2023.04.019
AMJMS 1887
To appear in:
The American Journal of the Medical Sciences
Received date:
Accepted date:
29 June 2022
20 April 2023
Please
cite
this
article
as:
Michael Hogarth M.D. ,
Daniel John ,
Yuxiang Li ,
Jessica Wang-Rodriguez M.D. ,
Jaideep Chakladar B.S., M.S. ,
Wei Tse Li B.S., M.S. ,
Sanjay R. Mehta M.D. , Sharad Jain M.D. , Weg M. Ongkeko M.D., Ph.D. , Clinical Characteristics and Comorbidities associated with SARS-CoV-2 breakthrough infection in the University
of California Healthcare Systems, The American Journal of the Medical Sciences (2023), doi:
https://doi.org/10.1016/j.amjms.2023.04.019
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2023 Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation.
Clinical Characteristics and Comorbidities associated with SARS-CoV-2 breakthrough infection
in the University of California Healthcare Systems
Authors: Michael Hogarth, M.D.1 †, Daniel John2,3, †, Yuxiang Li2,3, Jessica Wang-Rodriguez, M.D.
4,5
, Jaideep Chakladar, B.S., M.S. 2,3, Wei Tse Li, B.S., M.S.2,3, Sanjay R. Mehta, M.D.6, Sharad Jain,
M.D.7, and Weg M. Ongkeko, M.D., Ph.D.2,3, *
Affiliations:
1
Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
2
Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University
of California, San Diego, La Jolla, CA 92093, USA
3
Research Service, VA San Diego Healthcare System, San Diego, CA 92161, USA
4
Department of Pathology, University of California, San Diego, La Jolla, CA 92093, USA
5
Pathology Service, VA San Diego Healthcare System, San Diego, CA 92161, USA
6
Division of Infectious Diseases and Global Public Health, Department of Medicine,
University of California San Diego, La Jolla, CA, 92093, USA
7
The University of California Davis School of Medicine, Sacramento, CA 95817, USA
* Correspondence: rongkeko@health.ucsd.edu; Tel.: (858) 552-8585 X 7165
† The first two authors, (MH, DJ) contributed equally.
Keywords: COVID-19, breakthroughs, vaccination, comorbidities
Abstract
Background
To evaluate the degree to which clinical comorbidities or combinations of comorbidities are
associated with SARS-CoV-2 breakthrough infection.
Methods
A breakthrough infection was defined as a positive test at least 14 days after a full vaccination
regimen. Logistic regression was used to calculate aORs, which were adjusted for age, sex, and
race information.
Results
A total of 110,380 patients from the UC CORDS database were..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit